Penumbra (PEN) versus Masimo Corporation (MASI) Head to Head Comparison

Masimo Corporation (NASDAQ: MASI) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitabiliy, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Masimo Corporation and Penumbra, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Masimo Corporation 0 4 1 0 2.20
Penumbra 0 0 2 0 3.00

Masimo Corporation currently has a consensus price target of $75.67, suggesting a potential downside of 19.45%. Penumbra has a consensus price target of $95.00, suggesting a potential upside of 5.03%. Given Penumbra’s stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than Masimo Corporation.


This table compares Masimo Corporation and Penumbra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Masimo Corporation 44.86% 24.19% 15.00%
Penumbra -2.31% -2.25% -1.96%

Institutional and Insider Ownership

83.5% of Masimo Corporation shares are held by institutional investors. Comparatively, 68.7% of Penumbra shares are held by institutional investors. 16.6% of Masimo Corporation shares are held by company insiders. Comparatively, 22.0% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Masimo Corporation has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Valuation and Earnings

This table compares Masimo Corporation and Penumbra’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Masimo Corporation $709.76 million 6.77 $171.03 million $5.88 15.98
Penumbra $278.61 million 10.92 -$2.82 million ($0.21) -430.71

Masimo Corporation has higher revenue and earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than Masimo Corporation, indicating that it is currently the more affordable of the two stocks.


Masimo Corporation beats Penumbra on 8 of the 13 factors compared between the two stocks.

Masimo Corporation Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.

Penumbra Company Profile

Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *